FLUOPANC-trial - Fluorescence-guided Surgery of Pancreatic and Bileduct Tumors Using cRGD-ZW800-1
Status:
Not yet recruiting
Trial end date:
2024-07-30
Target enrollment:
Participant gender:
Summary
Pancreas as well as Cholangiocarcinoma have a dismal prognosis at time of diagnosis, due to
late onset of clinical symptoms, patients present with advance disease. Complete surgical
resection is the only potential curative treatment, however only a small percentage is
eligible for upfront total surgical resection due to extension into anatomical related
important vascular structures. Neoadjuvant chemo(radio)therapy has become the standard
treatment modality for non-primary resectable disease (borderline resectable and locally
advanced pancreatic cancer (LAPC)), where subsequent downstaging can make identification of
the primary tumor more challenging during surgery. Near-infrared (NIR) fluorescence imaging
can aid surgeons by providing real-time visualization of tumors, suspect lymph nodes and
vital structures during surgery. Additional intra-operative feedback could possibly reduce
the frequency of positive resection margins and increase complete removal of locally spread
tumor and involved lymph nodes and could thereby improve patient outcomes as well as overall
survival. cRGD-ZW800-1 is a targeted NIR-fluorophore, with specific binding capacity for
integrins (αvβ3, αvβ5, αvβ6) which are overexpressed on tumor cells and tumor-associated
vascular endothelium associated with neoangiogenesis.